Results 51 to 60 of about 900,797 (391)

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

Frontiers in Pharmacology, 2018
Background: Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient.
S. Millar, N. Stone, A. Yates, S. O’Sullivan   +3 more
semanticscholar   +1 more source

Intermediate role of gut microbiota in vitamin B nutrition and its influences on human health

Frontiers in Nutrition, 2022
Vitamin B consists of a group of water-soluble micronutrients that are mainly derived from the daily diet. They serve as cofactors, mediating multiple metabolic pathways in humans.
Zhijie Wan, Jianheng Zheng, Zhigang Zhu, Lan Sang, Jinwei Zhu, Shizheng Luo, Yixin Zhao, Ruirui Wang, Yicui Zhang, Kun Hao, Liang Chen, Jun Du, Juntao Kan, Hua He   +13 more
doaj   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Clinical Pharmacokinetics, 2019
Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor outcomes; however, only 20–40% of patients will show long-lasting survival. Further clarification
M. Centanni, D. Moes, I. Trocóniz, J. Ciccolini, J. G. V. van Hasselt   +4 more
semanticscholar   +1 more source

Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]

, 2018
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez, C Varenhorst, D Alexopoulos, D Aradi, D Lindholm, D Zhou, EA Amsterdam, F Franchi, G Parodi, G Parodi, H Sillén, HS Smith, J Kubica, J Kubica, J Li, JH Cornel, JM Siller-Matula, K Butler, K Butler, K Thygesen, M Koziński, M Roffi, P Adamski, P Adamski, P Adamski, P Adamski, P Niezgoda, P Niezgoda, PG Steg, PG Steg, PT O’Gara, R Teng, R Teng, R Teng, R Teng, R Teng, R Teng, RA Lange, S Husted, S James, SE Husted, SS Brar   +41 more
core   +2 more sources

An Investigation on Glucuronidation Metabolite Identification, Isozyme Contribution, and Species Differences of GL-V9 In Vitro and In Vivo

Molecules, 2019
GL-V9 is a prominent derivative of wogonin with a wide therapeutic spectrum and potent anti-tumor activity. The metabolism characteristics of GL-V9 remain unclear.
Han Xing, Dexuan Kong, Chen Ning, Ying Kong, Chang Ren, Yujie Cheng, Hui Cai, Jubo Wang, Di Zhao, Ning Li, Xijing Chen, Zhiyu Li, Yang Lu   +12 more
doaj   +1 more source

Food intake attenuates the drug interaction between new quinolones and aluminum

Journal of Pharmaceutical Health Care and Sciences, 2018
Background Intestinal absorption of new quinolones is decreased by oral administration of polyvalent metal cations. Some clinical studies have demonstrated this drug - drug interaction is more prominent under fasted condition. However, the effect of food
Ayuko Imaoka, Kosuke Abiru, Takeshi Akiyoshi, Hisakazu Ohtani   +3 more
doaj   +1 more source

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction

CPT: Pharmacometrics & Systems Pharmacology, 2019
Physiologically‐based pharmacokinetic (PBPK) modeling is a powerful tool to quantitatively describe drug disposition profiles in vivo, thereby providing an alternative to predict drug–drug interactions (DDIs) that have not been tested clinically.
Shinji Yamazaki, Chester Costales, Sarah Lazzaro, Soraya Eatemadpour, Emi Kimoto, Manthena V. Varma   +5 more
doaj   +1 more source

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114

CPT: Pharmacometrics & Systems Pharmacology, 2022
TAS‐114 is a dual deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD) inhibitor expected to widen the therapeutic index of capecitabine.
Hikari Araki, Toru Takenaka, Koichi Takahashi, Fumiaki Yamashita, Kazuaki Matsuoka, Kunihiro Yoshisue, Ichiro Ieiri   +6 more
doaj   +1 more source

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Clinical Pharmacokinetics, 2018
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer.
F. D. de Man, A. Goey, R. V. van Schaik, R. Mathijssen, S. Bins   +4 more
semanticscholar   +1 more source

The heterogeneity among subgroups of haplogroup J influencing Alzheimer’s disease risk

Journal of Advanced Research, 2021
Introduction: The impact of mitochondrial haplogroups on Alzheimer’s disease (AD) risk has not been fully elucidated and warrants further investigation at the subgroup level.
HaoChen Liu, Yixuan Zhang, Huimin Zhao, Yanan Du, XiaoQuan Liu   +4 more
doaj   +1 more source